HIV

Pharmacy students must have a comprehensive understanding of antiretrovirals to ensure efficiency and optimization of patients’ medical treatment.

The risk of developing HZ in this population is 10 to 30 times higher than in the general population.

As HIV treatment and prevention evolve, the use of long-acting injectables and their role in combating the HIV epidemic grows.

Results highlight promising advancements in novel treatments for patients with HIV-1, including a combination regimen with broadly neutralizing antibodies and long-term data on bictegravir, emtricitabine, and tenofovir alafenamide (Biktarvy).

Data from conference abstracts and presentations indicate that both preexposure prophylaxis methods continue to demonstrate efficacy.

Building on a previous report that revealed corrupt business practices among the big 3 PBMs, a second interim report finds that PBMs heightened prices for important specialty generic drugs to increase their profit margins.

Pharmacists' accessibility and expertise in medication management make them ideal health care providers to discuss prevention strategies, medication adherence, and potential adverse effects.

Pharmacy students can provide education, patient advocacy, and medication access.

Adding HIV/AIDS to core chronic diseases is a key change.

OraQuick was the first at-home HIV test kit to be approved by the FDA in 2012.

Pharmacists can bridge gaps through education, inclusive care, and streamlined access.

Islatravir in combination with lenacapavir could become the first weekly oral HIV treatment.

Cabotegravir long-acting when used for HIV pre-exposure prophylaxis (PrEP) showed adherence, effectiveness, and improvements in quality of life by those who received the injection.

Pharmacists should be aware of workplace hazards involving sharps and, if necessary, initiate oPEP.

The study findings signal the need for improved equality in PrEP prescribing across various institutions and settings.

These results build off the PURPOSE 1 trial, contributing to the wealth of evidence surrounding lenacapavir’s positive effects in patients with HIV.

Medication therapy management reimbursement can be a driving factor to work toward statin implementation in this patient group.

Cholesterol-lowering agents, like statins, reduced the risk of major adverse cardiovascular events and cardiovascular disease in patients with HIV.

Dolutegravir/lamivudine was non-inferior to bictegravir/emtricitabine/tenofovir alafenamide fumarate, meeting the study’s primary end point.

The experimental drug successfully reduced levels of SIV, the nonhuman primate equivalent of HIV, in the brain.

An extension of a long-acting cabotegravir study shows safety prior to and during pregnancy in cisgender women, with full results being presented at the 2024 International AIDS Conference.

Adherence and efficacy were both higher in patients with HIV who took twice-yearly lenacapavir compared to those on oral preexposure prophylaxis medication.

The shift is intended to maintain uninterrupted access to PrEP, crucial for preventing HIV, and highlights the ongoing efforts to end the HIV epidemic by improving public health outcomes.

Previous studies have shown that individuals living with HIV are at higher risk for heart disease than individuals without HIV

Study investigators hired undercover shoppers, and the results revealed more education is needed on the Syringe Service Program, which provides legal, clean over-the-counter (OTC) needles to whomever seeks them out.

The approval is based on data from Study 5310, evaluating the pharmacokinetics, safety, and efficacy of Biktarvy (Gilead Sciences Inc) in pregnant individuals.

The treatment is indicated for adolescents at least 12 years of age who weigh at least 25 kg without a previous treatment history of antiretroviral therapies.

Rilpivirine (Edurant Ped; Johnson and Johnson) is indicated for the treatment of HIV in combination with other antiretroviral therapies in treatment-naïve pediatric patients.

This grant funding is a part of the company’s 3-year Setting the P.A.C.E. initiative.